Compare KTOS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTOS | GH |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 13.3B |
| IPO Year | 1999 | 2018 |
| Metric | KTOS | GH |
|---|---|---|
| Price | $83.58 | $84.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 20 |
| Target Price | $97.44 | ★ $117.80 |
| AVG Volume (30 Days) | ★ 4.0M | 1.7M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | 6.74 |
| EPS | ★ 0.13 | N/A |
| Revenue | $751,900,000.00 | ★ $982,021,000.00 |
| Revenue This Year | $24.96 | $33.40 |
| Revenue Next Year | $23.89 | $28.55 |
| P/E Ratio | $714.62 | ★ N/A |
| Revenue Growth | 12.44 | ★ 32.88 |
| 52 Week Low | $27.51 | $36.36 |
| 52 Week High | $134.00 | $120.74 |
| Indicator | KTOS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 34.88 |
| Support Level | $82.27 | $82.26 |
| Resistance Level | $95.85 | $103.16 |
| Average True Range (ATR) | 5.67 | 3.94 |
| MACD | 0.25 | 0.07 |
| Stochastic Oscillator | 12.87 | 19.92 |
Kratos Defense & Security Solutions Inc develops and fields transformative, affordable technology, platforms, and systems. The company has two segments; The Kratos Government Solutions (KGS) segment is comprised of an aggregation of KGS operating segments, including its microwave electronic products, space, training, and cybersecurity, C5ISR/modular systems, turbine technologies, and defense and rocket support services operating segments and The Unmanned Systems segment consists of unmanned aerial, unmanned ground, unmanned seaborne and related command, control, and communications system businesses. The company derives a majority of its revenue from the Kratos Government Solutions segment.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.